Role of cardiovascular magnetic resonance in the prognosis of patients with myocardial infarction with non-obstructive coronary arteries

Nuria Vicente-Ibarra1, Eloisa Feliu2, Vicente Bertomeu-Martínez3, Pedro Cano-Vivar4, Pilar Carrillo-Sáez3, Pedro Morillas1 and Juan Miguel Ruiz-Nodar5,6*

Abstract

Background: It is estimated that 5% to 10% of patients with myocardial infarction (MI) present with no obstructive coronary artery lesions. Until now, most studies have focused on acute coronary syndrome, including different clinical entities with a similar presentation encompassed under the term MINOCA (MI with non-obstructive coronary arteries). The aim of this study is to assess the prognosis of patients diagnosed with true infarction, confirmed by cardiovascular magnetic resonance (CMR), in the absence of significant coronary lesions.

Methods: Prospective multicenter registry study, including 120 consecutive patients with a CMR-confirmed MI without obstructive coronary artery lesions. The primary clinical outcome was major adverse cardiovascular events (MACE: death, non-fatal infarction, stroke, or cardiac readmission), assessed over three years.

Results: Seventy-six patients (63.3%) were admitted with a diagnosis of acute coronary syndrome, and 44 (36.6%) for other causes (mainly heart failure); the definitive diagnosis was established by CMR. Most patients (64.2%) were men, and the mean age was 58.8 ± 13.5 years. Patients presented with small infarcts: 83 (69.1%) showed late gadolinium enhancement (LGE) in one or two myocardial segments, mainly transmural (in 77.5% of patients) and with a preserved left ventricular ejection fraction (median 54.8%, interquartile range 37–62). The most frequent infarct location was inferolateral (n = 38, 31.7%). During follow-up, 43 patients (35.8%) experienced a MACE, including 9 (7.5%) who died. In multivariable analysis, LGE in two versus one myocardial segment doubled the risk of adverse cardiac events (hazard ratio [HR] 2.32, 95% confidence interval [CI] 0.97–5.83, p = 0.058). Involvement of three or more myocardial segments almost tripled the risk (HR 2.71, 95% CI 1.04–7.04, p = 0.040 respectively).

Conclusions: Patients with true MI but without significant coronary artery lesions predominantly had small infarcts. Myocardial 3-segment LGE involvement is associated with a significantly higher risk of adverse cardiac events.

Keywords: Myocardial infarction with no obstructive coronary arteries, Cardiovascular magnetic resonance, Adverse cardiovascular events, Myocardial infarction

Background

The main physiopathological mechanism underlying acute coronary syndrome (ACS) is local and systemic inflammation, which provokes the rupture of an atheromatous plaque and subsequent coronary thrombosis [1].
Although ACS is generally associated with obstructive coronary artery disease, in up to 30% of these patients neither plaque nor thrombosis are visible in the coronary angiography [2]. This situation has occurred more frequently in recent years, in large part due to increased access to coronary angiography and the existence of more sensitive and specific troponins for diagnosing myocardial infarction (MI) [3]. These advances have led to the definition of a new entity, MI with non-obstructive coronary arteries (MINOCA), whose diagnosis is established when the coronary angiography shows the following features: (a) it meets universal criteria for MI; (b) the coronary angiogram shows no obstruction of the coronary arteries, defined as the absence of coronary diameter stenosis > 50% on any artery that is potentially responsible for the MI; and (c) there is no specific or overt clinical cause for acute presentation [4]. There are also non-ischemic or non-thrombotic clinical entities that can present with a similar clinical profile to myocardial infarction, such as myocarditis or Takotsubo syndrome. As their prognostic and therapeutic management are different, it is vital to reach an accurate diagnosis in these patients [5].

Cardiovascular magnetic resonance (CMR), especially when employing late gadolinium enhancement (LGE) techniques, is a highly sensitive, non-invasive imaging modality for detecting alterations of the myocardium, allowing identification of the etiology in 65% to 90% of cases with MINOCA [5–7]. Gadolinium is a low molecular weight compound that easily penetrates the capillary pores and spreads throughout the extracellular space. In a normal myocardium, it is washed out in a short period of time, whereas it builds up in the case of myocardial necrosis. The LGE study applies an inversion time, which nulls the signal from the normal myocardium (it appears hypoenhanced). This reveals the hyperenhanced myocardial necrosis with very high sensitivity. CMR is the only imaging technique capable of detecting small foci of fibrosis.

Several investigators have used CMR to analyze diverse cohorts of patients with ACS but without coronary obstruction in the angiographic study [5–19]. The results are not neatly concordant; most cases are considered myocarditis, while only a fraction are true infarctions. Therefore, the prognosis of patients diagnosed with MINOCA and having true MIs (free of the influence of non-ischemic entities) is not well defined. Moreover, the role of CMR for evaluating the prognosis of these patients is also unknown. The primary aim of this study is to assess the medium-term prognosis of patients with CMR-confirmed MI but without significant lesions on coronary angiography. Moreover, we investigate the morphological characterization of this type of MI on CMR and its relationship with adverse cardiac events during follow-up.

**Methods**

This was a multicenter descriptive, prospective study, with a small proportion of retrospectively included patients. We included consecutive patients from our CMR unit, referred from eight centers from May 2009 to June 2017, either during admission for an acute cardiologic event (ACS, heart failure, or ventricular tachycardia) or soon after discharge, when an invasive coronary angiography showed no significant coronary artery lesions. Patients were followed for a median of 2.9 years.

Exclusion criteria were: history of ischemic cardiomyopathy, regardless of revascularization; coronary diameter stenosis of > 50% on the conventional angiography; or midwall/subepicardial LGE with preserved endomyocardium (suggestive of myocarditis or other cardiomyopathies) or its absence on the LGE images.

During the study period, 27,752 coronarographies were performed in patients who had an initial diagnosis of ACS, chest pain, heart failure, or ventricular arrhythmia. CMRs were performed in 2198 of these patients, as indicated by the attending physician. The final study cohort consisted of 120 patients with subendocardial or transmural LGE, compatible with a defined coronary territory and absence of coronary artery diameter stenosis > 50% on angiography. Coronary artery angiograms were performed in three different centers. Studies were additionally reviewed in each one of those centers by another expert interventional cardiologist different from the one who had performed and reported the study. The patient flow chart is shown in Fig. 1.

![Fig. 1 Patient inclusion flowchart. *ACS acute coronary syndrome; CP chest pain; HF acute heart failure; CMR cardiovascular magnetic resonance; MI myocardial infarction; LGE late gadolinium enhancement](image-url)
Clinical and epidemiological variables as well as data related to the coronary angiography and post-discharge treatment were collected. The attending physicians decided on the drug treatment and disease management strategy. Investigators completed follow-up phone interviews and reviews of patients’ clinical records in 99.2% of the cases.

The estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) Study equation. All coronary angiograms were reviewed by a second expert interventional cardiologist. The study protocol complied with the Declaration of Helsinki and was approved by the research ethics committee of the reference hospital. All patients provided written informed consent.

Endpoints
The primary endpoint was the appearance of major adverse cardiovascular events (MACE) at follow-up, defined as death from any cause, non-fatal infarction, stroke, or cardiac readmission.

CMR protocol
CMR studies were performed using a 1.5 T CMR scanner (Intera, Philips Healthcare, Best, the Netherlands) and a multichannel phased-array antenna devoted to cardiac studies. All images were acquired during breath-holds and were electrocardiogram (ECG)-triggered. The following sequences were performed:

1. Cine Imaging (balanced steady-state free precession [bSSFP]) with at least 20 phases per cardiac cycle (8 mm slice thickness plus 2 mm gap; repetition time/echo time 3.3/1.65 ms; flip angle 60°; matrix 256 × 220). The following planes were obtained: two chamber, four chamber, three chamber and short axis with full left ventricle (LV) coverage from the mitral valve plane to the apex.

2. T2-STIR (short time inversion recovery) black blood sequence turbo spin echo [TSE] on short axis plane (slice thickness: 8 mm plus 2 mm gap, repetition time 2 × R to R interval (RR), echo time 100 ms, matrix 256 × 256).

3. LGE: T1-enhanced, 3-dimensional inversion recovery turbo gradient echo sequence (T1-turbo field echo, repetition time/echo time 4.0/1.24 ms; flip angle 15°; REC voxel MPS 1.5 × 1.5 mm), 10 min after administration of 0.1 mmol/kg of gadobutrol (Gadovist, Bayer Healthcare, Berlin, Germany) on two-chamber, four-chamber, and short axis planes (again covering the entire myocardium). The inversion time was adjusted individually to null the healthy myocardium, oscillating from 250 to 300 ms.

CMR analysis
One expert CMR radiologist performed the image analysis on an independent workstation provided by the manufacturer (View-Forum release 6.3, Philips Healthcare). In cine imaging, LV ejection fraction (LVEF) (%), end-diastolic volume (LVEDV) and end-systolic (ml/m²) volume (LVESV), as well as LV mass (g/m²) were calculated by semiautomatic planimetry of the endocardial and epicardial borders on all short-axis views. Also, right ventricle (RV) ejection fraction (RVEF) (%), end-diastolic volume (RVEDV), and end-systolic (ml/m²) volume (RVESV) were obtained, again by planimetry of the endocardial border on all short-axis views. A 17-segment model of the heart was used to visually determine the presence of either myocardial edema on T2-STIR weighted-images, or contrast enhancement on LGE images. When myocardial edema and LGE coincided, the finding was considered to be related to the acute onset. The inter and intra-observer variability for the quantification of all exposed CMR parameters in our unit has previously been determined as less than 5%.

Statistical analysis
Data were entered onto an Excel spreadsheet (Microsoft Corporation, Redmond, Washington, USA) and exported to Stata (version 13.1, StataCorp; College Station, Texas, USA). Categorical variables were expressed as absolute and relative frequencies, while continuous variables were assessed for normality using the Shapiro–Wilk test and expressed as mean and standard deviation (SD) or median and interquartile range (IQR), as appropriate.

Mortality and MACE observed during follow-up were expressed as percentages. Initially, a univariable analysis was performed to test the association between cardiovascular disease risk factors and comorbidity, analytical data and post-discharge treatment. Then a multivariable Cox regression was used to assess the relationship between predictor variables and cardiovascular events; the final model included all variables yielding a p value under 0.05 in univariable analysis, along with any other clinical variables that could plausibly influence the outcome, such as age, sex and different medical treatments upon discharge.

Results
Patients had a mean age of 58.8 years, and 64.2% were men. Half (51.7%) were hypertensive, while just 16.7% were diabetic. The main reason for ordering a coronary angiography was ACS (n = 76, 63.3%), followed by heart failure (n = 37, 30.8%) and ventricular arrhythmias.
A high proportion of patients presented arrhythmias at high thrombotic risk; 17 patients (14.2%) had a history of atrial fibrillation (AF). Another 12 patients (10%) were diagnosed with AF during their hospital stay, and 8 (6.7%) developed this condition during follow-up. All told, 11 patients (9.2%) presented an intraventricular thrombus.

On the angiography, 63.3% of the patients had angiographically normal coronary arteries, while 21.7% were described as having parietal irregularities or coronary artery ectasia, and 15% had non-significant (<50% obstruction) atherosclerotic lesions. Thirty-three patients (27.5%) underwent a ventriculography, and 65% presented segmental contractility abnormalities (Table 2).

The CMR was performed at a median of 12 days. LGE demonstrated transmural enhancement in 93 cases (77.5%), and subendocardial enhancement in 19 (15.8%). Eight patients (6.7%) had both types in two distinct regions (Fig. 2). Almost three-quarters of the patients (69.8%) presented with a small infarction on LGE, defined as enhancement in one or two LV segments. The most frequent infarct location was the inferolateral wall (Table 2; Fig. 2).

In the analysis of treatment upon discharge, we observed an underuse of all drugs recommended to treat ischemic cardiomyopathy; only 67.5% of patients were discharged with a prescription for angiotensin converting-enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs); 56.7%, beta-blockers; 59.2%, statins; and 60%, acetylsalicylic acid. Only a fifth of

| Table 1 | Baseline subject characteristics (N = 120) |
|---------|------------------------------------------|
| Variable | n (%)                                    |
| Age (years), mean ± SD | 58.8 ± 13.5 |
| Women | 43 (35.8) |
| Clinical presentation |                                      |
| ST-elevation ACS | 23 (19.2) |
| Non-ST elevation ACS | 53 (44.2) |
| Dilated cardiomyopathy and/or heart failure | 37 (30.8) |
| Ventricular arrhythmias | 7 (5.8) |
| Electrocardiogram |                                      |
| Sinus rhythm | 103 (85.8) |
| Atrial fibrillation | 17 (14.2) |
| ST elevation ≥ 2 leads or LBBB | 29 (24.2) |
| Non-ST elevation | 64 (53.3) |
| Comorbidities |                                      |
| Hypertension | 62 (51.7) |
| Diabetes mellitus | 20 (16.7) |
| Dyslipidemia | 40 (33.3) |
| Current smoking habit | 42 (35) |
| History of atrial fibrillation | 17 (14.2) |
| History of stroke/TIA | 7 (5.8) |
| Alcohol abuse | 19 (15.8) |
| Drug abuse | 12 (10) |
| eGFR (mL/min/1.73 m²), mean ± SD | 80 ± 34 |
| Treatment at discharge |                                      |
| Aspirin | 72 (60) |
| Dual antiplatelet therapy | 22 (18.3) |
| Oral anticoagulants | 38 (31.7) |
| Beta-blockers | 68 (56.7) |
| ACEI/ARB | 81 (67.5) |
| Statins | 71 (59.2) |

ACS acute coronary syndrome; LBBB left bundle branch block; TIA transient ischaemic attack; eGFR estimated glomerular filtration rate; ACEI angiotensin converting enzyme inhibitor; ARB angiotensin II receptor blocker; SD standard deviation

* Unless noted otherwise as mean ± SD

| Table 2 | Diagnostic imaging results |
|---------|-----------------------------|
| Coronary angiography, n (%) | 76 (63.3) |
| Parietal irregularities | 25 (20.9) |
| Non-obstructed coronary lesions | 18 (15) |
| Ectatic coronary arteries | 1 (0.8) |
| Ventriculography | 33 (27.5) |
| LV mass index (g/m²), median (IQR) | 97.2 (83.8–157.6) |
| Coronary angiography, n (%) | 76 (63.3) |
| Parietal irregularities | 25 (20.9) |
| Non-obstructed coronary lesions | 18 (15) |
| Ectatic coronary arteries | 1 (0.8) |
| Ventriculography | 33 (27.5) |
| LV mass index (g/m²), median (IQR) | 97.2 (83.8–157.6) |

LVEDVI left ventricular end-diastolic volume index; LVEF left ventricular ejection fraction; RVEDVI right ventricular end-diastolic volume index; RVESVI right ventricular end-systolic volume index; RVEF right ventricular ejection fraction;
the patients received dual anti-platelet therapy on discharge (Table 1).

**Follow-up**
Complete follow-up was achieved in 99.2% of the patients, for a median period of 2.9 (IQR 1.5–4.8) years. Nine patients (7.5%) died—2 from cardiovascular causes—and 7 (5.8%) presented a new non-fatal myocardial infarction. More than one third (35.8%) had a MACE (Table 3).

In the univariable analysis, low LVEF, LV dilatation, and MI size were associated with a poor prognosis. The involvement of two myocardial segments in CMR was associated with a twofold increased risk of MACE (hazard ratio [HR] 2.26, 95% confidence interval [CI] 0.98–5.19; p = 0.056) without reaching statistical significance; while involvement of three segments or more almost tripled that risk (HR 2.97, 95% CI 1.26–6.95, p = 0.012). The results in univariable analysis remained significant in multivariable analysis (Table 4; Fig. 3).

**Discussion**
This is the first registry study to assess the role of CMR for evaluating the prognosis of patients with true, CMR-confirmed MI and without significant lesions in the coronary arteries. Thus, we excluded other non-ischemic entities like myocarditis or Takotsubo syndrome. The results suggest that this entity is associated with a high incidence of MACE, including mortality.

To date, published studies have analyzed the clinical characteristics, treatment, and prognosis in patients with MI but without significant coronary lesions, focusing on a heterogeneous group of entities encompassed under MINOCA, including true MI, myocarditis, Takotsubo syndrome, and pulmonary thromboembolism [20]. These entities probably have differential prognoses and characteristics, so outcomes in this clinically diverse population cannot be extrapolated to patients with true MI but without significant lesions. Moreover, infarction in the absence of coronary artery lesions does not always occur in the context of an ACS; it can also present in other clinical scenarios like heart failure or ventricular arrhythmia. Thus, our series includes different forms of presentation in patients with CMR-confirmed MI and coronary artery lesions with obstruction under 50%.

In most published series on MINOCA, patients with an ACS but without significant lesions have been younger and more likely to be women than patients with obstructive lesions [21, 22]. Our sample confirms this tendency, with a younger mean age, a greater proportion of women, and a lower prevalence of risk factors (particularly diabetes) compared to ACS registries in the same population [23–25].

There are various mechanisms that can explain the existence of an infarct without the presence of coronary artery lesions, such as coronary spasm, a reperfused thrombus, misinterpretation of angiograms or microvascular dysfunction [26–28], or coronary artery embolization [29, 30]. This last cause could explain a large portion of the MIs in our cohort given the high prevalence of thrombotic arrhythmias (30.8%). Moreover, neurologists pointed to a probable embolic origin for all the strokes occurring during follow-up.

There was a notably low prescription rate for class I drugs indicated in clinical practice guidelines for secondary prevention of events in ischemic cardiomyopathy (aspirin, dual anti-platelet therapy, beta-blockers, ACEI/ARBs, and statins). This is probably attributable to the lower risk profile in these patients and to delays in diagnostic confirmation by CMR. Just 17.5% of the CMR studies were undertaken during the patients’ index hospitalization, which resulted in 74 (61.7%) patients being discharged with a diagnosis other than MI—modified only in follow-up. This brings to mind the most recent European guidelines for ACS with ST-segment elevation, which recommend performing CMR within two weeks of symptoms onset to optimize diagnostic accuracy and enable the best treatment decisions after the event [4]. Likewise, the new European Society of Cardiology guide for ACS without persistent ST-segment elevation includes a recommendation, with level 1b evidence, to perform CMR in all MINOCA patients [31]. Furthermore, a Swedish study [32] assessed drug treatments in major cardiovascular events (infarction, stroke, all-cause mortality, and admission due to heart failure), reporting beneficial effects for statins and ACEI/ARBs, a positive tendency for beta-blockers, and no effect for dual anti-platelet therapy. However, the study population consisted of all patients discharged from hospital with a diagnosis of acute MI and coronary artery stenosis of <50%. There
was no diagnostic confirmation of true infarctions, so other clinical entities with a similar presentation to ACS could have been included, including conditions with very different prognoses and therapeutic management. The underuse of medical treatment in this entity could contribute to the poor medium-term prognosis.

CMR is the most sensitive and specific technique for diagnosing abnormalities in MINOCA. In our series, patients presented with small infarcts: 83 (69.1%) showed LGE in one or two myocardial segments, mainly transmural (in 77.5% of patients) and with a conserved LVEF (median 54.8%, IQR 37–62). The most frequent location of the infarct was inferolateral (n = 38, 31.7%), with segment 14 (apical septal) remaining the least affected. Furthermore, CMR enables specification of the size and location of the MI, among other parameters that are closely related to the prognosis of patients with ischemic cardiomyopathy. In our study, multivariate analysis showed that the involvement of three or more myocardial segments estimated by CMR was associated with a threefold increase risk in adverse cardiac events in comparison with one-segment involvement (HR 2.97, 95% CI 1.26–6.95, p = 0.012).

### Table 3 Adverse events during follow-up in patients with true myocardial infarctions and coronaries without obstructive lesions

| Adverse events, n (%) | All patients | 1 segment | 2 segments | ≥ 3 segments |
|-----------------------|-------------|-----------|------------|-------------|
| MACEs                 | 43 (35.8)   | 8 (20)    | 19 (44.2)  | 16 (44.4)   |
| Non-fatal myocardial infarction | 7 (5.8)        | 0 (0)     | 3 (7)      | 4 (11.1)    |
| Ischemic stroke       | 4 (3.3)     | 1 (2.5)   | 1 (2.3)    | 2 (5.6)     |
| All-cause mortality   | 9 (7.5)     | 4 (10)    | 3 (7)      | 2 (5.6)     |
| Cardiovascular death  | 2 (1.7)     | 1 (2.5)   | 0 (0)      | 1 (2.8)     |
| Cardiovascular readmissions | 22 (18.3)  | 3 (7.5)   | 12 (27.9)  | 8 (22.2)    |
| Atrial fibrillation (all) | 37 (30.8)  | 9 (22.5)  | 18 (41.9)  | 10 (27)     |

* MACEs: major adverse events (non-fatal myocardial infarction or ischemic stroke or death of any cause or readmissions due to cardiac causes)

### Table 4 Independent predictors of adverse cardiovascular events during follow-up, Cox regression analysis

| Risk factors | Univariable analysis | p value | Multivariable analysis | p value |
|--------------|----------------------|---------|------------------------|---------|
| Age years    | 1.02 (0.99–1.04)     | 0.142   | 1.02 (0.99–1.02)       | 0.230   |
| Female sex   | 0.54 (2.27–1.08)     | 0.080   | 0.52 (0.24–1.14)       | 0.104   |
| Clinical presentation<sup>a</sup> | 1.25 (0.65–2.43) | 0.500   |                         |         |
| DCM and/or heart failure | 0.93 (0.32–2.70) | 0.901   |                         |         |
| Ventricular arrhythmias | 2.23 (1.16–4.31) | 0.017   | 2.19 (1.05–4.55)       | 0.036   |
| Renal insufficiency | 0.98 (0.96–0.99) | 0.027   | 1.00 (0.97–1.03)       | 0.781   |
| LVEF | 1.01 (1.00–1.02) | 0.009   | 1.00 (0.99–1.01)       | 1.180   |
| Myocardial segments with enhancement<sup>b</sup> | 2.26 (0.98–5.19) | 0.056   | 2.32 (0.97–5.83)       | 0.058   |
| 2 segments   | 2.97 (1.26–6.95)     | 0.012   | 2.71 (1.04–7.04)       | 0.040   |
| Aspirin      | 1.32 (0.72–2.44)     | 0.366   |                        |         |
| Dual antiplatelet therapy | 0.77 (0.42–1.43) | 0.417   |                        |         |
| Oral anticoagulants | 1.43 (0.77–2.65) | 0.257   |                        |         |
| Beta-blockers | 0.15 (0.62–2.14) | 0.663   |                        |         |
| ACEI/ARB     | 1.12 (0.58–2.16)     | 0.370   |                        |         |
| Statins      | 0.78 (0.42–1.45)     | 0.436   |                        |         |

<sup>a</sup> Reference: clinical presentation as ACS  
<sup>b</sup> Reference: involvement of a single segment of myocardial enhancement

HR: hazard ratio; CI: confidence interval; MACE: major adverse cardiovascular event; DCM: Dilated cardiomyopathy; LVEF: left ventricular ejection fraction; LVEDVI: left ventricular end-diastolic volume index on cardiac magnetic resonance; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin II receptor blockers
diagnostic tool; it could also determine the prognosis in patients with true MI but without significant coronary artery stenoses.

Until recently, scientific evidence on the prognosis of patients with ACS but without significant coronary artery stenoses was based only on a few small studies that indicated an excellent prognosis and high 10-year survival rates [33–35]. Emerging evidence shows a worse prognosis, with in-hospital mortality of 0.9% to 4.7% per year [36]. However, all these studies have taken place in the context of ACS, mixing clinical entities whose prognoses are not comparable, which could explain the great variability in the results. Our study, with a median follow-up of 2.9 years, describes a specific population of patients with true infarcts but without significant coronary artery lesions, indicating a poor prognosis. Although two-thirds of the participants had small MIs, the associated mortality was 7.5% and MACE rate was 35.8%. These data are more concordant with the general prognosis of patients with ischemic cardiomyopathy.

Limitations
Our study has several limitations. One of the limitations of this study is the missing data in baseline characteristics, which is typical of any registry like ours. Moreover, its observational nature makes it impossible to establish a causal relationship, although it does establish associations that can be tested in future studies. The fact that the study was observational also means that it did not influence how clinicians managed patients’ diagnosis and treatment, so CMR may have been underutilized in patients with acute events but no significant lesions. Another limitation is that no intracoronary imaging techniques were used; these may have identified acute ruptures in plaque that were not apparent on the conventional coronarography.

Fig. 3 Kaplan–Meier survival curve for MACE depending on the number of segments affected in the CMR. MACE: non-fatal myocardial infarction, ischemic stroke, death from any cause or readmissions due to cardiac causes

An additional limitation of the study is the existence of pathologies with findings that could be similar in CMR, such as sarcoid or hypereosinophilic syndromes. However, the clinical context, together with analytical data and other complementary tests, led us to the final diagnosis of MINOCA.

The study was in patients with CMR-confirmed MI but without significant coronary artery lesions, including patients with MINOCA but also other forms of presentation, such as ventricular arrhythmias or acute heart failure. We consider this to be the greatest strength of our study, as we included a population (CMR-diagnosed infarction) that has not been specifically studied up to now and whose prognosis was heretofore unknown.

Conclusions
Patients with CMR-confirmed true MI and without significant coronary artery stenoses have a poor medium-term prognosis, with a high incidence of cardiovascular events and mortality. This type of MI is predominantly
small. Involvement of three or more myocardial segments is associated with a significantly higher risk of adverse cardiac events. Our study reflects the importance of performing CMR in patients with MINOCA in order to improve the diagnosis of infarction and apply adequate secondary prevention measures.

Abbreviations
ACEI: Angiotensin converting enzyme inhibitor; ACS: Acute coronary syndrome; AF: Atrial fibrillation; ARB: Angiotensin receptor blocker; bSSFP: Balanced steady state free precession; CMR: Cardiovascular magnetic resonance; ECG: Electrocardiogram; eGFR: Estimated glomerular filtration rate; LGE: Late gadolinium enhancement; LV: Left ventricle/left ventricular; LVEDV: Left ventricular end-diastolic volume; LVEF: Left ventricular ejection fraction; LVESV: Left ventricular end-systolic volume; LVESVI: Left ventricular end-systolic volume index; MACE: Major adverse cardiovascular events; MI: Myocardial infarction; MINOCA: Myocardial infarction with no obstructive coronary arteries; RV: Right ventricle/right ventricular; RVEDV: Right ventricular end-diastolic volume; RVEF: Right ventricular ejection fraction; RVESV: Right ventricular end-systolic volume; RVESVI: Right ventricular end-systolic volume index; STIR: Short tau inversion recovery; TSE: Turbo spin echo.

Acknowledgements
Not applicable.

Authors’ contributions
VN, FE, RJ: Conception and design of project. FE, CVP, CSP, RJ: Data acquisition. Interventional cardiologist who reviewed the coronary angiography of each patient. FE, RJ: CMR sequence design and optimization. VN, FE, RJ: Collaboration in data interpretation and analysis. VN, FE, BV, MP, RJ: Manuscript draft and revision. All authors read and approved the final manuscript.

Funding
The manuscript has not received any funding.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The study protocol complied with the Declaration of Helsinki and was approved by the research ethics committee of the reference hospital (Elche University Hospital).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Cardiology Service, Elche University Hospital, Alicante, Spain. 2 Magnetic Resonance Imaging Unit, Irscanner S.L. General University Hospital of Alicante, Alicante, Spain. 3 Cardiology Service, San Juan General University Hospital, Alicante, Spain. 4 Cardiology Service. Santa Lucía General University Hospital. Cartagena, Murcia, Spain. 5 Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), General University Hospital of Alicante, Alicante, Spain. 6 Department of Cardiology, General University Hospital of Alicante, Alicante, Spain.

Received: 24 October 2020   Accepted: 5 May 2021
Published online: 01 July 2021

References
1. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104:365–72.
2. Johnston N, Jönelid B, Christersson C, Kero T, Renlund H, Schenck-Gustafsson K, et al. Effect of gender on patients with ST-elevation and non-ST-elevation myocardial infarction without obstructive coronary artery disease. Am J Cardiol. 2015;115:1661–6.
3. Ageval S, Eurenius L, Hofman-Bang C, Malmqvist K, Frick M, Jernberg T, et al. Myocardial infarction with angiographically normal coronary arteries. Atherosclerosis. 2011;219:10–4.
4. Ibanez B, James S, Ageval S, Artunes MJ, Bucciarelli-Ducci C, Bueno H, et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–77.
5. Leurent G, Langella B, Fougerot C, Lentz P-A, Larralde A, Bedossa M, et al. Diagnostic contributions of cardiac magnetic resonance imaging in patients presenting with elevated troponin, acute chest pain syndrome and unobstructed coronary arteries. Arch Cardiovasc Dis. 2011;104:161–70.
6. Assombu RG, Lyne JC, Keenan N, Gulati A, Bunce NH, Davies SW, et al. The role of cardiovascular magnetic resonance in patients presenting with chest pain, raised troponin, and unobstructed coronary arteries. Eur Heart J. 2007;28:1242–9.
7. Laraudogoitia E, Pérez-David E, Larena JA, Velasco del Castillo S, Rumoroso Cuevas JR, Onaindia JI, et al. The value of cardiac magnetic resonance in patients with acute coronary syndrome and normal coronary arteries. Rev Esp Cardiol. 2009;62:976–83.
8. Collste O, Sörensson P, Frick M, Agewall S, Daniel M, Henareh L, et al. Myocardial infarction with normal coronary arteries is common and associated with normal findings on cardiovascular magnetic resonance imaging: results from the Stockholm Myocardial Infarction with Normal Coronaries study. J Intern Med. 2013;273:189–96.
9. Stensæth KH, Fossum E, Hoffmann P, Mangschau A, Klow NE. Clinical characteristics and role of early cardiac magnetic resonance imaging in patients with suspected ST-elevation myocardial infarction and normal coronary arteries. Int J Cardiovasc Imaging. 2011;27:355–65.
10. Mahmoudi M, Harden S, Abid N, Peebles C, Nicholas Z, Jones T, et al. Troponin-positive chest pain with unobstructed coronary arteries: definitive differential diagnosis using cardiac MRI. Br J Radiol. 2012;85:e461–466.
11. Kawecki D, Morawiec B, Monney P, Pellaton C, Wojciechowska C, Jojko J, et al. Diagnostic contribution of cardiac magnetic resonance in patients with acute coronary syndrome and culprit-free angiograms. Med Sci Monit. 2015;21:171–80.
12. Christiansen JP, Edwards C, Sinclair T, Armstrong G, Scott A, Patel H, et al. Detection of myocardial scar by contrast-enhanced cardiac magnetic resonance imaging in patients with troponin-positive chest pain and minimal angiographic coronary artery disease. Am J Cardiol. 2006;97:768–71.
13. Hermens JA JM, van Es J, van Birgelen C, Opden Akker JW, Wagenaar LJ. Evidence of myocardial scarring and microvascular obstruction on cardiac magnetic resonance imaging in a series of patients presenting with myocardial infarction without obstructed coronary arteries. Int J Cardiovasc Imaging. 2014;30:1097–103.
14. Gerbaud E, Harcaut E, Coste P, Erickson M, Lederlin M, Labbègue I, et al. Cardiac magnetic resonance imaging for the diagnosis of patients presenting with chest pain, raised troponin, and unobstructed coronary arteries. Int J Cardiovasc Imaging. 2012;28:783–94.
15. Dasidag AR, Rodrigues JC, Ahmed N, Bantussio A, Bucciarelli-Ducci C. The role of cardiac MRI in patients with troponin-positive chest pain and unobstructed coronary arteries. Curr Cardiovasc Imaging Rep. 2015;8:28.
16. Steen H, Madadi-Schroeder M, Lehke S, Lossnitzer D, Giannitsis E, Katus HA. Staged cardiovascular magnetic resonance for differential diagnosis of troponin positive patients with low likelihood for acute coronary syndrome. J Cardiovasc Magn Reson. 2010;12:51.
17. Chu G, Zhang G, Zhu M, Zhang Z, Wu Y, Zhang H. Acute one-stop cardiovascular magnetic resonance imaging for differential diagnosis in patients with acute coronary syndrome and unobstructed coronary arteries. Med Princ Pract. Int J Kuwait Univ Health Sci Cent. 2015;24:325–31.
18. Saba L, Fellini F, De Filippo M. Diagnostic value of contrast-enhanced cardiac magnetic resonance in patients with acute coronary syndrome with normal coronary arteries. Jpn J Radiol. 2015;33:410–7.
19. Mather AN, Fairbairn TA, Artsi NJ, Greenwood JP, Plein S. Diagnostic value of CMR in patients with biomarker-positive acute chest pain and unobstructed coronary arteries. JACC Cardiovasc Imaging. 2010;3:661–4.
20. Dastidar AG, Baritussio A, De Garate E, Drobni Z, Biglino G, Singhal P, et al. Prognostic role of cardiac MR and conventional risk factors in myocardial infarction with nonobstructed coronary arteries. JACC Cardiovasc Imaging. 2019;12:1973–82.
21. Germing A, Lindstaedt M, Ulrich S, Grewe P, Bojara W, Lavo T, et al. Normal angiogram in acute coronary syndrome-preangiographic risk stratification, angiographic findings and follow-up. Int J Cardiol. 2005;99:19–23.
22. Da Costa A, Isaak K, Faure E, Mourot S, Cerisier A, Lamaud M. Clinical characteristics, aetiological factors and long-term prognosis of myocardial infarction with an absolutely normal coronary angiogram, a 3-year follow-up study of 91 patients. Eur Heart J. 2001;22:1459–65.
23. Orenes-Pihero E, Ruiz-Nodar JM, Esteve-Pastor MA, et al. Therapeutic management and one-year outcomes in elderly patients with acute coronary syndrome. Oncotarget. 2017;8:80182–91.
24. Rivera-Caravaca JM, Ruiz-Nodar JM, Tello-Montoliu A, Esteve-Pastor MA, Véliz-Martínez A, Orenes-Pihero E, et al. Low body weight and clinical outcomes in acute coronary syndrome patients: results of the ACHILLES Registry. Eur J Cardiovasc Nurs J Work Group Cardiovasc Nurs Eur Soc Cardiol. 2017;16:696–703.
25. Vicente-Ibarra N, Marín F, Pernías-Escrig V, Sandín-Rollán M, Núñez-Martínez L, Lozano T, et al. Impact of anemia as risk factor for major bleeding and mortality in patients with acute coronary syndrome. Eur J Intern Med. 2019;61:48–53.
26. Szatjel J, Mach F, Rigetti A. Role of the vascular endothelium in patients with angina pectoris or acute myocardial infarction with normal coronary arteries. Postgrad Med J. 2000;76:16–21.
27. Bulkley BH, Klacsmann PG, Hutchins GM. Angina pectoris, myocardial infarction and sudden cardiac death with normal coronary arteries: a clinicopathologic study of 9 patients with progressive systemic sclerosis. Am Heart J. 1978;95:563–9.
28. Sun H, Mohri M, Shimokawa H, Usui M, Urakami L, Takahata A. Coronary microvascular spasm causes myocardial ischemia in patients with vasospastic angina. J Am Coll Cardiol. 2002;39:847–51.
29. Erbel R, Heusch G. Coronary microembolization. J Am Coll Cardiol. 2000;36:22–4.
30. Alpert JS. Fascination with myocardial infarction and normal coronary arteries. Eur Heart J. 2001;22:1364–6.
31. Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42:1289–367.
32. Lindahl B, Baron T, Erlinge D, Hadziosmanovic N, Nordenskjold A, Gard A, et al. Medical therapy for secondary prevention and long-term outcome in patients with myocardial infarction with nonobstructive coronary artery disease. Circulation. 2017;135:1481–9.
33. Larsen AJ, Nilsen DWT, Yu J, Mehran R, Nikolsky E, Lansky AJ, et al. Long-term prognosis of patients presenting with ST-segment elevation myocardial infarction with no significant coronary artery disease (from the HORIZONS-AMI trial). Am J Cardiol. 2013;111:643–8.
34. Ammann P, Marschall S, Kraus M, Schmid L, Angehn W, Krapf R, et al. Characteristics and prognosis of myocardial infarction in patients with normal coronary arteries. Chest. 2000;117:333–8.
35. Chopard R, Jehl J, Duthiel J, Genon VO, Seronde M-F, Kastler B, et al. Evolution of acute coronary syndrome with normal coronary arteries and normal cardiac magnetic resonance imaging. Arch Cardiovasc Dis. 2011;104:509–17.
36. Pasupathy S, Air T, Dreyer RP, Tavella R, Beltrame JF. Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries. Circulation. 2015;131:861–70.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.